-- 
Boehringer’s BIBF 1120 as Effective as Bevacizumab in Patients

-- B y   R a j i v   S e k h r i
-- 
2011-09-27T07:21:10Z

-- http://www.bloomberg.com/news/2011-09-27/boehringer-s-bibf-1120-as-effective-as-bevacizumab-in-patients.html
Boehringer Ingelheim’s BIBF 1120 in
patients with metastatic colorectal cancer is as effective as
bevacizumab with less serious adverse events, results from a
Phase I/II study showed, the company said in an e-mailed
statement today.  To contact the editor responsible for this story:
Rajiv Sekhri at 
 rsekhri1@bloomberg.net  